DK0941738T3 - Antigene konjugater af bevarede lipooligosaccharider af gramnegative bakterier - Google Patents

Antigene konjugater af bevarede lipooligosaccharider af gramnegative bakterier

Info

Publication number
DK0941738T3
DK0941738T3 DK99301747T DK99301747T DK0941738T3 DK 0941738 T3 DK0941738 T3 DK 0941738T3 DK 99301747 T DK99301747 T DK 99301747T DK 99301747 T DK99301747 T DK 99301747T DK 0941738 T3 DK0941738 T3 DK 0941738T3
Authority
DK
Denmark
Prior art keywords
negative bacteria
conserved
gram
lipooligosaccharides
lipopolysaccharide
Prior art date
Application number
DK99301747T
Other languages
Danish (da)
English (en)
Inventor
Rasappa G Arumugham
Maria Fortuna-Nevin
Michael A Apicella
Bradford W Gibson
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21894823&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0941738(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of DK0941738T3 publication Critical patent/DK0941738T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK99301747T 1998-03-10 1999-03-09 Antigene konjugater af bevarede lipooligosaccharider af gramnegative bakterier DK0941738T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3752998A 1998-03-10 1998-03-10
EP99301747A EP0941738B1 (de) 1998-03-10 1999-03-09 Antigenkonjugate von konservierten Lipooligosacchariden aus gram-negativen Bakterien

Publications (1)

Publication Number Publication Date
DK0941738T3 true DK0941738T3 (da) 2005-08-08

Family

ID=21894823

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99301747T DK0941738T3 (da) 1998-03-10 1999-03-09 Antigene konjugater af bevarede lipooligosaccharider af gramnegative bakterier

Country Status (12)

Country Link
EP (1) EP0941738B1 (de)
JP (1) JPH11322793A (de)
KR (1) KR100628664B1 (de)
AT (1) ATE295181T1 (de)
AU (2) AU766184B2 (de)
BR (1) BR9902008A (de)
CA (1) CA2264970A1 (de)
DE (1) DE69925187T2 (de)
DK (1) DK0941738T3 (de)
ES (1) ES2241240T3 (de)
PT (1) PT941738E (de)
SI (1) SI0941738T1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE435028T1 (de) * 1999-09-30 2009-07-15 Isis Innovation Impfstoff gegen neisseria infektion
US7749511B2 (en) 2000-04-18 2010-07-06 Endobiologics, Incorporated Anti-sepsis conjugate vaccine
JP2004515450A (ja) 2000-04-18 2004-05-27 エンドバイオロジックス, インコーポレイテッド 敗血症処置のためのリポ多糖結合体ワクチン
JP2004506086A (ja) 2000-08-25 2004-02-26 アベンティス、パストゥール、リミテッド インフルエンザ菌感染症の予防用ワクチンとしてのインフルエンザ菌リポ多糖内部コアオリゴ糖エピトープ
WO2002020059A2 (en) * 2000-09-01 2002-03-14 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Vibrio cholerae o139 conjugate vaccines
EP1374892A1 (de) * 2002-06-28 2004-01-02 Braun, Jan Matthias, Dr. Arzneimittel zur Behandlung von infektiösen Krankheiten infolge Neisseria Meningitidis
KR101239242B1 (ko) 2002-08-02 2013-03-11 글락소스미스클라인 바이오로지칼즈 에스.에이. 항원 조합물을 포함하는 나이세리아 백신 조성물
WO2004043405A2 (en) 2002-11-12 2004-05-27 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
MY144231A (en) 2003-12-17 2011-08-15 Wyeth Corp Aß IMMUNOGENIC PEPTIDE CARRIER CONJUGATES AND METHODS OF PRODUCING SAME
EA012984B1 (ru) * 2003-12-17 2010-02-26 Вайет Конъюгаты иммуногенных пептидных носителей и способы их получения
ES2493440T3 (es) 2004-12-17 2014-09-11 De Staat Der Nederlanden, Vert. Door De Minister Van Vws, Ministerie Van Volksgezondheid, Welzijn En Sport Desacilación de LPS en bacterias Gram negativas
US8329184B2 (en) 2005-06-27 2012-12-11 Glaxosmithkline Biologicals S.A. Process for manufacturing vaccines
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
DE602007003596D1 (de) 2006-06-12 2010-01-14 Glaxosmithkline Biolog Sa Impfstoff
KR20110031393A (ko) 2008-07-21 2011-03-25 더 브리검 앤드 우먼즈 하스피털, 인크. 합성 베타-1,6 글루코사민 올리고당에 관한 방법 및 조성물
WO2010130896A2 (fr) 2009-05-14 2010-11-18 Sanofi Pasteur Procédé pour adjuver le lipopolysaccharide (lps) des bactéries à gram-négatif
WO2010130898A2 (fr) 2009-05-14 2010-11-18 Sanofi Pasteur Vaccin meningocoque a base de lipooligosaccharide (los) provenant de souches modifiees de neisseria meningitidis d'immunotype l6
WO2010134225A1 (ja) * 2009-05-20 2010-11-25 国立大学法人鳥取大学 部分糖鎖エピトープを用いた、病原性ナイセリア属細菌感染の検出方法およびそれら細菌に対するワクチン
CA2792683A1 (en) 2010-03-10 2011-09-15 Glaxosmithkline Biologicals S.A. Neisserial fhbp vaccine composition
AU2011262346B2 (en) 2010-06-04 2014-12-11 Wyeth Llc Streptococcus pneumoniae vaccine formulations
PL404229A1 (pl) 2013-06-06 2014-12-08 Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością Wyizolowany immunogenny antygen bakteryjny i jego zastosowanie w profilaktyce i leczeniu zakażeń wywołanych przez Gram-ujemne bakterie
CN103308686B (zh) * 2013-06-28 2016-04-06 武汉云克隆科技股份有限公司 脂多糖酶联免疫吸附测定试剂盒的制备方法
KR101509456B1 (ko) * 2013-10-04 2015-04-14 아이진 주식회사 리포폴리사카라이드 유사체 및 이를 포함하는 면역보조 조성물
CN104352762A (zh) * 2014-12-11 2015-02-18 谭清平 一种用于治疗脓毒症的中药及其制备方法
MX2019002489A (es) 2016-09-02 2019-10-21 Sanofi Pasteur Inc Vacuna contra neisseria meningitidis.
US20230137821A1 (en) * 2016-11-25 2023-05-04 Glaxosmithkline Biologicals, S.A. Immunogenic conjugates and use thereof
CN112125832B (zh) * 2020-08-12 2022-09-20 北京大学 刺突蛋白受体结合结构域纳米凝胶及其制备方法与应用
JP2024510334A (ja) * 2021-03-15 2024-03-06 グリフィス・ユニバーシティ 病原体部分及びその用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887483B2 (en) * 1995-12-01 2005-05-03 University Of Iowa Research Foundation Non-toxic mutants of pathogenic gram-negative bacteria

Also Published As

Publication number Publication date
JPH11322793A (ja) 1999-11-24
AU766184B2 (en) 2003-10-09
ATE295181T1 (de) 2005-05-15
AU2004200060B2 (en) 2005-10-13
CA2264970A1 (en) 1999-09-10
DE69925187T2 (de) 2006-03-09
DE69925187D1 (de) 2005-06-16
KR19990077705A (ko) 1999-10-25
BR9902008A (pt) 2000-05-09
AU1954099A (en) 1999-09-23
SI0941738T1 (en) 2005-10-31
ES2241240T3 (es) 2005-10-16
KR100628664B1 (ko) 2006-09-27
PT941738E (pt) 2005-09-30
AU2004200060A1 (en) 2004-01-29
EP0941738B1 (de) 2005-05-11
EP0941738A1 (de) 1999-09-15

Similar Documents

Publication Publication Date Title
DK0941738T3 (da) Antigene konjugater af bevarede lipooligosaccharider af gramnegative bakterier
FI862370A (fi) Monoklonaalisia vasta-aineita syklosporiineille
ATE397456T1 (de) Enterokokkus antigene und vakzine
WO1998058668A3 (en) Bordetella pertussis antigens as carriers in vaccinating conjugates and oral vaccines comprising bordetella pertussis fimbriae
NO902909L (no) T-celle-epitop som baerermolekyl for konjugat-vaksiner.
AU570405B2 (en) Conjugates of muramyl-peptides and haptenes
EP0694309A3 (de) Vakzine, Antigene und Antikörper enthaltende Zusammensetzung für den Schutz und die Hemmung von durch Staphylococcus induzierten Infektionen
ES553425A0 (es) Perfeccionamientos en la fabricacion de conjugados de proteinas portadores de antigenos inmunogenicos para vacunas contra la malaria
DK101196A (da) Histaminderivat, histamin-immunogen-konjugat samt antistof fremstillet mod konjugatet
DE59707944D1 (de) Elektromotor
AU3841993A (en) Synthetic lipid a glycoconjugate antigens for use in vaccines